Asunto(s)
Leucemia/epidemiología , Linfoma/epidemiología , Adolescente , Factores de Edad , Linfoma de Burkitt/epidemiología , Niño , Preescolar , Interpretación Estadística de Datos , Femenino , Enfermedad de Hodgkin/epidemiología , Humanos , Lactante , Recién Nacido , Leucemia Mieloide Aguda/epidemiología , Modelos Lineales , Linfoma no Hodgkin/epidemiología , Masculino , Distribución de Poisson , Leucemia-Linfoma Linfoblástico de Células Precursoras/epidemiología , Sistema de Registros , República de Belarús/epidemiología , Factores SexualesRESUMEN
The effectiveness of polychemotherapy (platidiam + chemoradiation treatment) for extensive cancer of the esophagus, stomach and lung was studied in 71 patients. Response rate in esophageal cancer patients after platidiam, methotrexate and prospidin was 31%, which increased to 65% after irradiation. In stomach cancer patients treated with platidiam, 5-fluorouracil and vincristine, antitumor effect was registered in 30% and a 50% regression of tumor following radiotherapy--in 37%. In small cell lung cancer group, chemotherapy (platidiam + cyclophosphamide + vincristine) was effective in 37.5% and in 83% when combined with radiotherapy.
Asunto(s)
Carcinoma de Células Pequeñas/tratamiento farmacológico , Cisplatino/uso terapéutico , Neoplasias Esofágicas/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Gástricas/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Pequeñas/radioterapia , Cisplatino/efectos adversos , Terapia Combinada , Evaluación de Medicamentos , Neoplasias Esofágicas/radioterapia , Humanos , Neoplasias Pulmonares/radioterapia , Metástasis Linfática , Dosificación Radioterapéutica , Inducción de Remisión , Neoplasias Gástricas/radioterapia , Factores de TiempoRESUMEN
The report deals with an analysis of the results of treatment of 84 patients suffering small cell lung cancer. Four regimens of combination chemotherapy as well as radiation were used. Complete plus partial regression rates ranged 18-81% (mean-42%) following chemotherapy and 73-87% after radiation treatment. Platidiam-containing schemes proved most effective. Prophylactic cranial irradiation was followed by increased survival. A correlation between extent of tumor and effectiveness of treatment was established.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Pequeñas/terapia , Neoplasias Pulmonares/terapia , Adulto , Carcinoma de Células Pequeñas/tratamiento farmacológico , Carcinoma de Células Pequeñas/radioterapia , Cisplatino/administración & dosificación , Terapia Combinada , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/radioterapia , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Procarbazina/administración & dosificación , Prospidio/administración & dosificación , Vincristina/administración & dosificaciónRESUMEN
Vascularization of laryngeal tumors in 79 patients was determined using a specially devised method. According to the quantity of capillaries in a visual field 3 degrees of vascularization were singled out. A close correlation between the vascularization of tumors and their radiocurability was revealed. In poorly vascularized tumors the local regression and 5-year survival were significantly lower than those in richly vascularized tumors.
Asunto(s)
Carcinoma de Células Escamosas/irrigación sanguínea , Neoplasias Laríngeas/irrigación sanguínea , Tolerancia a Radiación , Capilares , Carcinoma de Células Escamosas/mortalidad , Carcinoma de Células Escamosas/radioterapia , Humanos , Neoplasias Laríngeas/mortalidad , Neoplasias Laríngeas/radioterapia , PronósticoRESUMEN
The results of therapy of 112 patients with squamous cell laryngeal carcinoma, Stage III, were analysed. All the patients were given gamma-beam therapy by a split course. The first group was composed of 29 patients who received radiotherapy alone, 33 patients of the 2nd group also received chemotherapy with methotrexate, 5 mg daily, and 50 patients of the 3rd group were given radiotherapy and methotrexate, 60 mg once a week. Somewhat better short- and long-term results were achieved in the 2nd group. Statistically significant difference was obtained depending on the immediate efficacy of radio- and chemotherapy: 5-year survival rates in complete tumor regression were 57.1 +/- 7,7%, and in the presence of a residual tumor 26.3 +/- 7.2%. Radiation reactions and complications were more frequently observed in patients on radiotherapy combined with methotrexate, 60 mg once a week.